Adaptív és maladaptív jelátviteli mechanizmusok vizsgálata humán és emlôs szívben
és agyszövetben(K 138090) Funder: NRDIO
Rianopátiák kórélettana és gyógyszertana(FK 135130) Funder: NRDIO
DE-SPACE(TKP2020-NKA-04) Funder: NRDIO
Subjects:
Clinical medicine
Cardiovascular diseases
Cardiac and Cardiovascular systems
Cardiac diseases are the leading causes of death, with a growing number of cases worldwide,
posing a challenge for both healthcare and research. Therefore, the most relevant
aim of cardiac research is to unravel the molecular pathomechanisms and identify new
therapeutic targets. Cardiac ryanodine receptor (RyR2), the Ca2+ release channel of
the sarcoplasmic reticulum, is believed to be a good therapeutic target in a group
of certain heart diseases, collectively called cardiac ryanopathies. Ryanopathies
are associated with the impaired function of the RyR, leading to heart diseases such
as congestive heart failure (CHF), catecholaminergic polymorphic ventricular tachycardia
(CPVT), arrhythmogenic right ventricular dysplasia type 2 (ARVD2), and calcium release
deficiency syndrome (CRDS). The aim of the current review is to provide a short insight
into the pathological mechanisms of ryanopathies and discuss the pharmacological approaches
targeting RyR2.
